Brief: 3D Signatures says completion of Stage 3 of Hodgkin's Lymphoma Test Validation Program

Telo Genomics

10/10/2017 14:04

Oct 10 (Reuters) - 3d Signatures Inc  DXD.V : 
    * On September 30, co completed clinical trial component or stage 3, of its 
Hodgkin's Lymphoma Test Validation Program 
    * Remain on track for expected commercial launch of Telo-HL(TM )as an LDT by 
end of Q1 2018 
 
Source text for Eikon:  ID:nGNXOEUVZa  
Further company coverage:  DXD.V  
 
 ((Bangalore.newsroom@thomsonreuters.com;))